Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 17;169(8):167.
doi: 10.1007/s00705-024-06095-3.

GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection

Changqing Liu #  1 , Shan Li #  2 , Muchuan Qiao  1 , Chenlu Zeng  1 , Xiaomin Liu  3 , Yunlian Tang  4
Affiliations
Review

GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection

Changqing Liu et al. Arch Virol. .

Abstract

Epstein‒Barr virus (EBV) is a double-stranded DNA virus belonging to the family Orthoherpesviridae that is associated with the development of various tumors, such as lymphoma, nasopharyngeal carcinoma, and gastric cancer. There are no uniformly effective treatments for human EBV infection, and vaccines and immunotherapies are currently the main research directions. The glycoproteins gB and gH/gL are surface glycoproteins that are common to all herpesviruses, with subtle differences in structure and function between different viruses. The core membrane fusion machinery constituted by EBV gB and gH/gL is an important target of neutralizing antibodies in epithelial EBV infection due to its essential role in the fusion of viral and target cell membranes. In this article, we review the main modes of EBV infection, the structure and function of the core fusion machinery gB and gH/gL, and the development of neutralizing antibodies and prophylactic vaccines based on this target.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Epstein MA, Achong BG, Barr YM (1964) Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 1(7335):702–703 - PubMed
    1. Cui X, Snapper CM (2021) Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Front Immunol 12:734471 - PubMed - PMC
    1. Wong Y et al (2022) Estimating the global burden of Epstein-Barr virus-related cancers. J Cancer Res Clin Oncol 148(1):31–46 - PubMed
    1. Overkamp M, Quintanilla-Martinez L, Fend F (2022) EBV-associated lymphoproliferative disorders. Pathologie (Heidelb) 43(4):282–291 - PubMed
    1. Damania B, Kenney SC, Raab-Traub N (2022) Epstein-Barr virus: Biology and clinical disease. Cell 185(20):3652–3670 - PubMed - PMC

MeSH terms

LinkOut - more resources